Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.

This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.

This review discusses the limitations of existing clinician-reported outcome measures for alopecia areata and emphasizes the need for a composite scoring system to better assess disease severity.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This study found that using calcipotriene and betamethasone dipropionate cream in a real-world setting significantly improved clinical outcomes and patient quality of life for adults with mild-to-moderate scalp psoriasis, especially among those with higher adherence, demonstrating high treatment satisfaction.

This study found that high-dose UVA-1 therapy appeared to improve both patient-reported outcomes and objective clinical measures in patients with morphea and systemic sclerosis, supporting its potential efficacy for treating scleroderma.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.

This review identified various outcome measure instruments for assessing androgenetic alopecia but found inconsistent application across clinical trials, underscoring the need for standardized assessment methods.

JAK inhibitors help regrow eyebrow and eyelash hair and improve anxiety and depression in some alopecia areata patients.

This qualitative study reported that platelet-rich plasma treatments improved patient satisfaction and quality of life by enhancing facial texture and hair quality, supporting PRP as a viable option for conditions like alopecia and skin rejuvenation.

This study from China found that although traditional surgical techniques remain common, endoscopic-assisted surgery is linked with higher patient-reported satisfaction, suggesting its valuable potential for broader application in clinical settings. Factors like reduced bra cup size, surgical method, and implant placement influenced patient satisfaction.

This study of hirsutism in Chennai found idiopathic causes most common and reported that both Nd YAG and IPL lasers had a 70% good response rate in hair removal across different skin types.

This study found that the Hair Mass Index is suitable for quantifying hair loss, but patient self-assessment is the most reliable method for evaluating chemotherapy-induced alopecia in clinical practice.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

The study on androgenetic alopecia reported that microneedling with concentrated growth factor significantly improved hair regrowth in patients over two years, without age influencing the outcome, and recorded no significant adverse reactions.

This review discusses patient-reported outcomes for health-related quality of life in cutaneous lupus erythematosus and reports no new clinical results; the authors note limited existing research and recommend further studies.

This study examined the clinicopathological characteristics of cutaneous squamous cell carcinoma on the scalp and ear but reported no new results on its association with androgenetic alopecia.

This study observed that platelet-rich plasma therapy significantly improved hair density and diameter in patients with androgenetic alopecia, with no treatment-related adverse effects reported.

This protocol outlines a study aiming to develop a universal patient-reported outcome measure for various hair disorders through qualitative interviews, with no new clinical results reported yet.

This study reported that the combination of tacrolimus, clobetasol, and minoxidil improved hair measurements and stabilized inflammation in primary cicatricial alopecia patients, with most tolerating the treatment well.

This literature review found a significant increase in men seeking non-surgical and surgical cosmetic procedures, driven by improved self-confidence, with high efficacy and satisfaction reported by specialists providing advanced, patient-focused care.

This study found that autologous platelet-rich plasma significantly improved hair follicle number, thickness, and density in patients with androgenic alopecia compared to placebo, with high reported patient satisfaction.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

The measures for eyebrow and eyelash hair loss in severe Alopecia Areata are reliable and useful for clinical trials.

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

This study found that patient-reported outcomes revealed the persistence of neuropathy, insomnia, and nail changes in breast cancer patients beyond chemotherapy, emphasizing the importance of monitoring long-term adverse events.

In this study, researchers used a patient-reported outcome questionnaire to assess long-term adverse effects in breast cancer patients undergoing chemotherapy, finding persistent symptoms like neuropathy, dysgeusia, insomnia, and nail loss. Peripheral neuropathy was notably prolonged in those receiving anthracycline- and taxane-based regimens compared to docetaxel/cyclophosphamide.

This systematic review reported positive outcomes with gender-affirming hormone therapy in Canada and emphasized the urgent need for standardized outcome measurement tools to enhance evidence-based practices.